Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
Journal of Clinical Endocrinology and Metabolism, Volume 107, No. 9, Year 2022
Notification
URL copied to clipboard!
Description
Background and Aims: Metabolic-associated fatty liver disease (MAFLD) was proposed as a better definition of nonalcoholic fatty liver disease (NAFLD) to encompass the metabolic dysregulation associated with NAFLD. This redefinition challenges our understanding of the disease. Hence, this study sought to conduct an updated analysis of the prevalence, clinical characteristics, and associated factors of MAFLD, with a further sensitivity analysis done based on lean and nonobese MAFLD individuals. Methods: Medline and Embase databases were searched to include articles on MAFLD. Meta-analysis of proportions was conducted using the generalized linear mix model. Associating factors were evaluated in conventional pairwise meta-analysis with sensitivity analysis on lean and nonobese MAFLD. Results: From pooled analysis involving 3 320 108 individuals, the overall prevalence of MAFLD was 38.77% (95% CI 32.94% to 44.95%); 5.37% (95% CI 4.36% to 6.59%) and 29.78% (95% CI 26.06% to 33.79%) of lean and nonobese individuals, respectively, had MAFLD. Metabolic complications such as hypertension [odds ratio (OR) 2.63, 95% CI 1.85 to 3.74, P<0.0001 and OR 2.03; 95% CI 1.74 to 2.38, P<0.0001, respectively] and diabetes (OR 3.80, 95% CI 2.65 to 5.43, P<0.0001 and OR 3.46, 95% CI 2.81 to 4.27, P<0.0001, respectively) were found as significant associating factors associated with lean and nonobese MAFLD. Conclusions: This meta-analysis supports previous studies in reporting MAFLD to affect more than a third of the global population. While exploration of the pathogenic basis of fatty liver disease without metabolic dysregulation is required, the emphasis on management of concomitant metabolic disease in MAFLD can improve multidisciplinary efforts in managing the complex disease. © 2022 The Author(s). Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved.
Authors & Co-Authors
Chan, M. Y.
Singapore, Singapore City
National University of Singapore
Singapore, Singapore City
National University Hospital
Kaewdech, Apichat
Thailand, Hatyai
Prince of Songkla University
Dan, Yock Young
Singapore, Singapore City
National University of Singapore
Singapore, Singapore City
National University Hospital
Noureddin, Mazen
United States, Los Angeles
Cedars-sinai Medical Center
Eslam, Mohammed
Australia, Parramatta
The Westmead Institute for Medical Research
Statistics
Citations: 69
Authors: 5
Affiliations: 7
Identifiers
Doi:
10.1210/clinem/dgac321
ISSN:
0021972X
Research Areas
Noncommunicable Diseases
Study Design
Cross Sectional Study
Case-Control Study
Study Approach
Systematic review